Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application

Year of Publication: 2020
Contained in: Journal of autoimmunity Vol. 111 (2020), p. 102452
All journal articles: Search for all articles in this journal
Language: English
Contributors: Liu, Bingwen | Author
Li, Min
Zhou, Zhiguang
Guan, Xuan
Xiang, Yufei
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Coronavirus disease 2019
Cytokine release syndrome
I031V2H011
IL6 protein, human
Journal Article
Research Support, Non-U.S. Gov't
Review
Tocilizumab
tocilizumab
Additional Keywords: Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Betacoronavirus
Coronavirus Infections
Cytokine Release Syndrome
Humans
Immunomodulation
Interleukin-6
Pandemics
Pneumonia, Viral
Severe Acute Respiratory Syndrome
ISSN: 1095-9157
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 11.06.2020
Date Revised 11.06.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32291137
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.jaut.2020.102452
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04164nma a2200865 c 4500
001 NLM309613019
003 DE-601
005 20200715032803.0
007 cr uuu---uuuuu
008 200415s2020 000 0 eng d
024 7 |a 10.1016/j.jaut.2020.102452  |2 doi 
028 5 2 |a pubmed20n1229.xml 
035 |a S0896-8411(20)30067-6 
035 |a (DE-599)NLM32291137 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Liu, Bingwen 
245 1 0 |a Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 11.06.2020 
500 |a Date Revised 11.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Elsevier Ltd. All rights reserved. 
520 |a The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Research Support, Non-U.S. Gov't  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Anti-Inflammatory Agents  |6 D000893  |a therapeutic use  |6 Q000627 
653 2 |a Antibodies, Monoclonal, Humanized  |6 D061067  |a *therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640  |a pathogenicity  |6 Q000472 
653 2 |a Coronavirus Infections  |6 D018352  |a *pathology  |6 Q000473 
653 2 |a Cytokine Release Syndrome  |6 D000080424  |a *therapy  |6 Q000628 
653 2 |a Humans  |6 D006801 
653 2 |a Immunomodulation  |6 D056747  |a drug effects  |6 Q000187 
653 2 |a Interleukin-6  |6 D015850  |a *antagonists & inhibitors  |6 Q000037  |a blood  |6 Q000097 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *pathology  |6 Q000473 
653 2 |a Severe Acute Respiratory Syndrome  |6 D045169  |a pathology  |6 Q000473 
655 7 |a Coronavirus disease 2019  |2 gnd 
655 7 |a Cytokine release syndrome  |2 gnd 
655 7 |a Interleukin-6  |2 gnd 
655 7 |a Tocilizumab  |2 gnd 
655 7 |a Anti-Inflammatory Agents  |2 gnd 
655 7 |a Antibodies, Monoclonal, Humanized  |2 gnd 
655 7 |a IL6 protein, human  |2 gnd 
655 7 |a Interleukin-6  |2 gnd 
655 7 |a tocilizumab  |2 gnd 
655 7 |a I031V2H011  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Research Support, Non-U.S. Gov't 
689 0 2 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Coronavirus disease 2019 
689 1 1 |a Cytokine release syndrome 
689 1 2 |a Interleukin-6 
689 1 3 |a Tocilizumab 
689 1 |5 DE-601 
689 2 0 |a Anti-Inflammatory Agents 
689 2 1 |a Antibodies, Monoclonal, Humanized 
689 2 2 |a IL6 protein, human 
689 2 3 |a Interleukin-6 
689 2 4 |a tocilizumab 
689 2 5 |A r  |a I031V2H011 
689 2 |5 DE-601 
700 1 |a Li, Min 
700 1 |a Zhou, Zhiguang 
700 1 |a Guan, Xuan 
700 1 |a Xiang, Yufei 
773 0 8 |i in  |t Journal of autoimmunity  |g Vol. 111 (2020), p. 102452  |q 111<102452  |w (DE-601)NLM012637564  |x 1095-9157 
856 4 1 |u http://dx.doi.org/10.1016/j.jaut.2020.102452  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 111  |j 2020  |b 11  |c 06  |h 102452